Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Acquisitions & Divestments: 2021-2025

Historic Change in Acquisitions & Divestments for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Sep 2025 value amounting to $32.9 million.

  • 4D Molecular Therapeutics' Change in Acquisitions & Divestments fell 49.24% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $367.0 million, marking a year-over-year increase of 178.59%. This contributed to the annual value of $169.0 million for FY2024, which is 2.48% down from last year.
  • 4D Molecular Therapeutics' Change in Acquisitions & Divestments amounted to $32.9 million in Q3 2025, which was down 67.60% from $101.6 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Change in Acquisitions & Divestments ranged from a high of $205.3 million in Q3 2022 and a low of -$135.2 million during Q4 2022.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $55.5 million (2023), whereas its average is $58.5 million.
  • In the last 5 years, 4D Molecular Therapeutics' Change in Acquisitions & Divestments plummeted by 2,803.88% in 2022 and then spiked by 1,027.88% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $5.0 million in 2021, then crashed by 2,803.88% to -$135.2 million in 2022, then skyrocketed by 121.09% to $28.5 million in 2023, then surged by 130.72% to $65.8 million in 2024, then plummeted by 49.24% to $32.9 million in 2025.
  • Its Change in Acquisitions & Divestments was $32.9 million in Q3 2025, compared to $101.6 million in Q2 2025 and $166.7 million in Q1 2025.